The Johns Hopkins Oncology Center is dedicated to research and education in cancer and related disorders and to the prompt application of new knowledge to the treatment of patients and to the prevention of neoplastic diseases. In order to address these goals, the Medical Institutions created an Oncology Faculty and Endowment and constructed a Center facility which houses research laboratories and special clinical services. There is a broad base of ongoing cancer research at Johns Hopkins. The special scientific programs of the Oncology Center are interdisciplinary in character and are focused on human disease. A wide range of activity is encompassed ranging from fundamental research into the molecular genetics of human tumorigenesis to clinical trials of new antitumor treatments. The seven major research programs of the Center are administered by Divisions: Bone Marrow Transplantation (Santos), Cancer Biology (Baylin), Pharmacology and Experimental Therapeutics (Colvin), Radiological Science (Order), Medical Oncology (Abeloff), Pediatric Oncology (Civin), and Developmental Academic Programs (Coffey). Special educational opportunities in oncology are open to a wide variety of students at all levels of education and experience. The emphasis on the biology and treatment of human neoplasia is especially pertinent to physician-scientists. Community outreach activities include professional education and clinical research as well as patient consultation and treatment programs. Under the aegis of the State Health Department, the Center is joined with other agencies to address the cancer problems extant in the Maryland area, as well as the needs of special population groups such as minorities, the elderly, and rural residents.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA006973-32
Application #
2084553
Study Section
Cancer Center Support Review Committee (CCS)
Project Start
1978-01-01
Project End
1996-04-30
Budget Start
1994-05-01
Budget End
1995-04-30
Support Year
32
Fiscal Year
1994
Total Cost
Indirect Cost
Name
Johns Hopkins University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
045911138
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Bharti, Santosh K; Mironchik, Yelena; Wildes, Flonne et al. (2018) Metabolic consequences of HIF silencing in a triple negative human breast cancer xenograft. Oncotarget 9:15326-15339
Jackson, Sadhana; Weingart, Jon; Nduom, Edjah K et al. (2018) The effect of an adenosine A2A agonist on intra-tumoral concentrations of temozolomide in patients with recurrent glioblastoma. Fluids Barriers CNS 15:2
Dejea, Christine M; Fathi, Payam; Craig, John M et al. (2018) Patients with familial adenomatous polyposis harbor colonic biofilms containing tumorigenic bacteria. Science 359:592-597
Gorin, Michael A; Rowe, Steven P; Patel, Hiten D et al. (2018) Prostate Specific Membrane Antigen Targeted 18F-DCFPyL Positron Emission Tomography/Computerized Tomography for the Preoperative Staging of High Risk Prostate Cancer: Results of a Prospective, Phase II, Single Center Study. J Urol 199:126-132
Jiang, Wei; Zhou, Xiaoyan; Li, Zengxia et al. (2018) Prolyl 4-hydroxylase 2 promotes B-cell lymphoma progression via hydroxylation of Carabin. Blood 131:1325-1336
Nagai, Kozo; Hou, Lihong; Li, Li et al. (2018) Combination of ATO with FLT3 TKIs eliminates FLT3/ITD+ leukemia cells through reduced expression of FLT3. Oncotarget 9:32885-32899
Sturgeon, Kathleen M; Hackley, Renata; Fornash, Anna et al. (2018) Strategic recruitment of an ethnically diverse cohort of overweight survivors of breast cancer with lymphedema. Cancer 124:95-104
Baena-Del Valle, Javier A; Zheng, Qizhi; Esopi, David M et al. (2018) MYC drives overexpression of telomerase RNA (hTR/TERC) in prostate cancer. J Pathol 244:11-24
Antonarakis, Emmanuel S; Lu, Changxue; Luber, Brandon et al. (2018) Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and Enzalutamide. Eur Urol 74:218-225
Zarif, Jelani C; Antonarakis, Emmanuel S (2018) Targeting ELK1: a wELKome addition to the prostate cancer armamentarium. AME Med J 3:

Showing the most recent 10 out of 2393 publications